On March 8, 2022 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA (Press release, Sana Biotechnology, MAR 8, 2022, View Source [SID1234609740]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Sana’s hypoimmune platform has the potential to enable transplants of allogeneic cells without immunosuppression, including allogeneic CAR T cells. Hypoimmune cells were engineered to eliminate HLA-I, HLA-II, and TCR expression to block activation of T cells and B cells, as well as prevent graft versus host disease, while also overexpressing CD47 to block both natural killer cell and macrophage killing. The preclinical data demonstrate these hypoimmunogenic CAR T cells are able to evade both the innate and adaptive arms of the immune system while retaining their antitumor activity.
Sana is utilizing this hypoimmune platform to develop a portfolio of allogeneic CAR T cell therapies for patients with cancer, starting with CD19-expressing B cell malignancies such as non-Hodgkin’s lymphoma. Sana expects to file investigational new drug applications for multiple product candidates that utilize this platform, starting with SC291 (CD19) in 2022 and SC276 (CD19/CD22) as early as 2023.
Poster details:
Title: Engineered hypoimmune allogeneic CAR T cells as potential off-the-shelf CAR T cell immunotherapies
Session Category: Immunology
Session Title: Preclinical Immunotherapy
Abstract Number: 5598
Full abstracts are available for viewing in the AACR (Free AACR Whitepaper) Online Itinerary Planner located here, View Source!/10517. The full e-poster will be available Friday, April 8, 2022 at 1:00 p.m. ET and remain available for viewing through Wednesday, July 13, 2022.